NO985636L - aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier - Google Patents

aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier

Info

Publication number
NO985636L
NO985636L NO985636A NO985636A NO985636L NO 985636 L NO985636 L NO 985636L NO 985636 A NO985636 A NO 985636A NO 985636 A NO985636 A NO 985636A NO 985636 L NO985636 L NO 985636L
Authority
NO
Norway
Prior art keywords
apl
conjugates
methods
treating
antibody
Prior art date
Application number
NO985636A
Other languages
English (en)
Norwegian (no)
Other versions
NO985636D0 (no
Inventor
Edward Jess Victoria
David Matthew Marquis
David S Jones
Lin Yu
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/660,092 external-priority patent/US6207160B1/en
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of NO985636D0 publication Critical patent/NO985636D0/no
Publication of NO985636L publication Critical patent/NO985636L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
NO985636A 1996-06-06 1998-12-03 aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier NO985636L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/660,092 US6207160B1 (en) 1995-06-07 1996-06-06 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
US76050896A 1996-12-05 1996-12-05
PCT/US1997/010075 WO1997046251A1 (en) 1996-06-06 1997-06-06 aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES

Publications (2)

Publication Number Publication Date
NO985636D0 NO985636D0 (no) 1998-12-03
NO985636L true NO985636L (no) 1999-02-08

Family

ID=27097975

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985636A NO985636L (no) 1996-06-06 1998-12-03 aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier

Country Status (7)

Country Link
EP (1) EP0954531A1 (ko)
JP (1) JP2000512981A (ko)
KR (1) KR20000016414A (ko)
AU (1) AU734638B2 (ko)
CA (1) CA2256449A1 (ko)
NO (1) NO985636L (ko)
WO (1) WO1997046251A1 (ko)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164395T1 (de) * 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
IL140918A0 (en) 1998-07-27 2002-02-10 Genentech Inc Improved transformation efficiency in phage display through modification of a coat protein
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
GB9919452D0 (en) * 1999-08-17 1999-10-20 Osteometer Biotech As Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases
AU7646100A (en) * 1999-11-05 2001-05-14 Novozymes A/S A high throughput screening (hts) method
KR20020059808A (ko) 1999-11-28 2002-07-13 와이즈먼 앤드루 항체 친화도에 기초한 루프스 치료방법 및 그것의 사용을위한 스크리닝 방법과 조성물
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
KR101287395B1 (ko) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 BLyS에 결합하는 항체
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
AU2001285066B2 (en) 2000-08-18 2006-06-29 Human Genome Sciences, Inc. Binding polypeptides for B lymphocyte stimulator protein (BLYS)
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
AU2002257142B2 (en) 2001-04-13 2008-09-04 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK2000545T3 (da) 2001-06-20 2011-11-28 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
DK2423335T3 (da) 2001-06-21 2014-08-18 Dynavax Tech Corp Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
NZ573740A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ538628A (en) 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
ES2751414T5 (es) 2003-07-08 2024-04-23 Novartis Pharma Ag Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
ES2472690T3 (es) 2003-11-17 2014-07-02 Genentech, Inc. Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
KR101268877B1 (ko) 2004-09-01 2013-05-31 다이나박스 테크놀로지 코퍼레이션 선천성 면역반응 및 자가면역의 억제를 위한 방법 및조성물
KR20070110077A (ko) 2005-03-10 2007-11-15 제넨테크, 인크. 혈관 완전성을 조정하기 위한 방법 및 조성물
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2061904A2 (en) 2006-09-06 2009-05-27 Ortho-McNeil Pharmaceutical, Inc. Biomarkers for assessing response to c-met treatment
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
WO2009055076A2 (en) 2007-10-26 2009-04-30 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
KR20110038047A (ko) 2008-06-20 2011-04-13 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 산화 LDL/β2GPI복합체에 대한 항체 및 그 용도
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
MX2012004617A (es) 2009-10-22 2012-05-08 Genentech Inc Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
MX338694B (es) 2009-11-30 2016-04-27 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
PE20130214A1 (es) 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
EP2566893A1 (en) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
CA2802873C (en) 2010-06-16 2018-09-18 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
EP2654772B1 (en) * 2010-12-22 2018-09-26 The Salk Institute for Biological Studies Cyclic crf antagonist peptides
GB2503604B (en) 2011-03-21 2020-04-22 Biodesy Llc Classification of kinase inhibitors using second harmonic optical techniques
RU2014109395A (ru) 2011-09-15 2015-10-20 Дженентек, Инк. Способы стимуляции дифференциации
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック, インコーポレイテッド 癌を治療するためのscd1アンタゴニスト
EP2804630B1 (en) 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
RU2014141617A (ru) 2012-03-16 2016-05-10 Дженентек, Инк. Сконструированные конформационно-стабилизированные белки
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
BR112014020173A8 (pt) 2012-03-16 2017-07-11 Hoffmann La Roche Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção
CN104583776B (zh) 2012-04-25 2016-09-07 比奥德赛公司 用于检测蛋白质的变构调节剂的方法
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP4356960A2 (en) 2013-03-15 2024-04-24 F. Hoffmann-La Roche AG Biomarkers and methods of treating pd-1 and pd-l1 related conditions
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
CN114057857A (zh) 2014-06-20 2022-02-18 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
CN113795514A (zh) 2019-05-09 2021-12-14 豪夫迈·罗氏有限公司 制备抗体的方法
CN112480209B (zh) * 2020-11-16 2022-03-04 昆明学院 一种抗皮肤光损伤保护活性多肽rl-pl9及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006006A1 (fr) * 1989-10-19 1991-05-02 Yamasa Shoyu Kabushiki Kaisha Excipient de liaison d'anticorps antiphospholipides, immuno-analyse utilisant cet excipient et kit associe
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
ATE127925T1 (de) * 1990-04-06 1995-09-15 Yamasa Shoyu Kk Verfahren zur bestimmung von antiphospholipid antikörpern.
WO1991015722A1 (de) * 1990-04-10 1991-10-17 Masur, Walter Verfahren zum betreiben einer kompressionswärmepumpe, sowie kompressionswärmepumpe
EP1808183A3 (en) * 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

Also Published As

Publication number Publication date
WO1997046251A1 (en) 1997-12-11
KR20000016414A (ko) 2000-03-25
AU3640497A (en) 1998-01-05
NO985636D0 (no) 1998-12-03
JP2000512981A (ja) 2000-10-03
EP0954531A1 (en) 1999-11-10
AU734638B2 (en) 2001-06-21
EP0954531A4 (en) 1999-08-31
CA2256449A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
NO985636L (no) aPL immunoreaktive peptider, konjugater derav og metoder for behandling av aPL antistoff-medierte patologier
EP0833648A4 (en) PLA IMMUNE REACTION PEPTIDES, CONJUGATES THEREOF, AND METHODS OF TREATING DISEASES INDUCED BY PLA ANTIBODIES
DE69730043D1 (de) Implantierbare eletrodenleitung
HUP0003401A3 (en) Improved methods for processing activated protein c
ZA9811593B (en) Substantially pure histidine-linked protein polymer conjugates
ZA986072B (en) Adsorption apparatus and methods.
DE69725567D1 (de) Haltetransplantat
ZA97631B (en) Migraine treatment.
IL118969A0 (en) Purse string suture apparatus
EP0911397A4 (en) TUMORANTANT PROTEINS, THEIR GENES, AND TUMORANTANT PEPTIDES
EP0904539A4 (en) INHIBITION OF PROTEIN INTERACTION
GB2311840B (en) UV dryer with improved reflector
GB9606126D0 (en) Biosensors
ZA973211B (en) Support post.
IL117674A0 (en) UV reflector
DE29606585U1 (de) Karussel
GB2318340B (en) Envelope closing apparatus
ZA968185B (en) Protein.
ZA989574B (en) Indole derivative useful in therapy.
TR199600586A3 (tr) Ürün ve hizmetlerin karsiliginin ödenmesi için proses.
KR970052847U (ko) 시트 제품 적재 장치
GB9706674D0 (en) UV Dryers
ZA968224B (en) Hair-styling apparatus.
BR9705072A (pt) Aparelho de difusão
AU787P (en) APRIL GLO Prunus persica var. nucipersica

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application